Update in methodology and conduct of cancer clinical trials

European Journal of Cancer

Volumn 42, Issue 10, 2006, Pages 1322-1330

  Therasse, P ^a   Eisenhauer, E A ^a   Buyse, M ^a  

^a EORTC DATA CENTER   (Belgium)

Author keywords

Clinical trial directive; Interim analysis; RECIST

Indexed keywords

BEVACIZUMAB; CYTOTOXIC AGENT; ERLOTINIB;

ARTICLE; CANCER; CANCER PATIENT; CLINICAL TRIAL; DATA ANALYSIS; DRUG EFFICACY; ETHICS; EUROPE; HUMAN; IMAGING; MEDICAL RESEARCH; METHODOLOGY; MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; STATISTICAL MODEL;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DIAGNOSTIC IMAGING; EUROPE; HUMANS; NEOPLASMS;

EID: 33745157948     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.02.006     Document Type: Article

References (20)

1. Miller A.B., Hogestraeten B., Staquet M., and Winkler A. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
2. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New Guidelines to Evaluate the Response to Treatment in Solid Tumours. J Natl Cancer Inst 92 (2000) 205-216
3. Park J.O., Lee S.I., Song S.Y., et al. Measuring response in solid tumours: comparison of RECIST and WHO. Jpn J Clin Oncol 33 (2003) 533-537
4. Sohaib S.A., Turner B., Hanson J.A., Farquharson M., Oliver R.T.D., and Reznek R.H. CT assessment of tumour response to treatment: comparison of linear, cross-sectional and volumetric measures of tumour size. Br J Radiol 73 (2000) 1178-1184
5. Trillet-Lenoir V., Freyer G., Kaemmerlen P., et al. Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria. Br J Radiol 75 (2002) 903-908
6. Werner-Wasik M., Xiao Y., Pequignot E., Currant W.J., and Hauck W. Assessment of lung cancer response after nonoperative therapy: tumour diameter, bidimensional product, and volume. A serial CT scan-based study. Int J Radiat Oncol Biol Phys 51 (2001) 56-61
7. Therasse P., Le Cesne A., Van Glabbeke M., Verweij J., Judson I., and for the EORTC Soft Tissue and Bone Sarcoma Group. RECIST vs WHO: Prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma. Eur J Cancer 41 (2005) 1426-1430
8. Hillman S.L., Sargent D.J., An M.W., et al. Evaluation of RECIST criteria in determining the response to treatment in solid tumours: A North Central Cancer Treatment Group (NCCTG) investigation. Proc Am Soc Clin Oncol 22 (2003) 521 (abstr 2095)
9. Schwartz L.H., Mazumdar M., Brown M., Smith A., and Panicek D.M. Variability in response assessment in solid tumours: effect of number of lesions chosen for measurements. Clin Cancer Res 9 (2003) 4318-4323
10. Ratain M.J., and Eckhardt S.G. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol 22 Nov 15 (2004) 4442-4445
11. Kelloff G.J., Krohn K.A., Larson S.M., et al. The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res 22 (2005) 7967-7985
12. Kelloff G.J., Hoffman J.M., Johnson B., et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 8 (2005) 2785-2808
13. DeMets D.L., Furberg C.D., and Friedman L. Data Monitoring in Clinical Trials. A Case Studies Approach (2005), Springer Verlag, Heidelberg
14. Ellenberg S.S., Fleming T.R., and DeMets D.L. Data Monitoring Committees in Clinical Trials. A Practical Perspective (2002), John Wiley & Sons, New York
15. Jennison C., and Turnbull B. Group Sequential Methods with Applications to Clinical Trials (1999), Chapman & Hall/CRC, Boca Raton, FL
16. Piantadosi S. Clinical Trials A Methodologic Perspective (1997), John Wiley & Son, New York
17. Directive 2001/20/ECof the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products. Official Journal of the European Communities 1.5.2001.
18. Lacombe D., Rea L.A., and Meunier F. New EU legislation may hinder academic clinical cancer research. EJHP 3 (2003) 14-18
19. Baeyens A.J., and Lacombe D. Regulatory issues for clinical trials at EORTC: the way forward. Eur J Cancer 38 (2002) S142-S146
20. Debbaudt A., Roche L., Lacombe D., and Baeyens A.J. EORTC's Regulatory Affairs Unit; Facilitating European Cancer Research. Applied Clinical Trials Sept (2002) 61-66